Published in BMC Proc on September 24, 2008
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol (2007) 3.50
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res (2007) 3.18
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol (2005) 2.84
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist (2008) 2.53
Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer (2007) 1.53
Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist (2007) 1.26
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist (2005) 1.24
The place of targeted therapy in the patient management of non-small cell lung cancer. Lung Cancer (2007) 0.86
Targeted therapies and non-small-cell lung cancer: new developments. Curr Opin Oncol (2007) 0.82
Latest developments in the treatment of lung cancer. BMC Proc (2008) 0.75